Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423371 · ClinicalTrials.gov registry record · Phase 2
Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC
A Phase 2 study of Osteoarthritis, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
- 1
- Study location
NCT00423371: Completed Phase 2 study of Osteoarthritis, sponsored by Ferring Pharmaceuticals.
NCT00423371 is a Phase 2 study of Osteoarthritis that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 79 participants, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00423371, a Phase 2 study of Osteoarthritis, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
- 1
- Study location
Study Summary
This multicenter, double-blind, randomized, parallel-group, active-controlled trial will be performed in approximately 80 subjects with chronic idiopathic osteoarthritis (OA) of the first carpo-metacarpal joint (CMC).
Conditions Studied
Interventions
- DEVICE sodium hyaluronate
- DEVICE placebo
Study Locations (1)
Florida
- All Florida Orthopedic Association - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00423371 record still lists
NCT00423371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which sodium hyaluronate is the first listed.
NCT00423371 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00423371 about?
NCT00423371 is a clinical study titled "Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC". This multicenter, double-blind, randomized, parallel-group, active-controlled trial will be performed in approximately 80 subjects with chronic idiopathic osteoarthritis (OA) of the first carpo-metacarpal joint (CMC).
What is the current status of trial NCT00423371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2006-12. Estimated completion is 2007-09.
What conditions does trial NCT00423371 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT00423371?
The interventions under investigation include: sodium hyaluronate (DEVICE), placebo (DEVICE).
Who is sponsoring clinical trial NCT00423371?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00423371 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00423371's enrollment target sits among peer trials
79 102nd of 135 higher than 34 of 135 other Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
RECRUITING · Phase 2
-
Platelet Rich Plasma Injections In Young And Old Human Subjects
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia